The European Medicines Agency's publication of a draft policy that would make detailed data on drugs publicly available after they are approved could deter crucial investment in Europe, said Chris Viehbacher, CEO of Sanofi and president of the European Federation of Pharmaceutical Industries and Associations. The Pharmaceutical Research and Manufacturers of America has condemned EMA's plans to unveil clinical-trial information, saying it could weaken research incentives and harm business.

Full Story:

Related Summaries